GREY:IPHAF - Post by User
Post by
biodelatechon Aug 20, 2005 3:27am
262 Views
Post# 9436759
potential sales for 247
potential sales for 247neoral (cyclosporin) had worldwide sales of $1.2 billion in 2001.
I think it´s been declining since then , due to generic competition.
I think 247 can easily surpass that, given its better side-effects-profile, once it is approved for psoriasis and transplant rejection. And what´s more, 247 won´t be attacked by generics for a long time.